In the European pharmaceutical industry, there were 15 private equity deals announced in Q2 2024, worth a total value of $18.3m, according to GlobalData’s Deals Database. The $17m investment by TVM Capital Healthcare Partners in NeuroCare Group was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes and the Private Equity deal activity are included in GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, private equity deal activity in Europe decreased by 96% in Q2 2024 compared with the previous quarter’s total of $402.4m and fell by 95% as compared to Q2 2023. Related deal volume decreased by 29% in Q2 2024 versus the previous quarter and was 46% lower than in Q2 2023.
The top-ranked financial advisors supporting these private equity deals in Europe in H1 2024 were Deloitte Touche Tohmatsu; KPMG International Coop; Bank of America with 2, 2, 1 deals respectively.
The top-ranked legal advisors supporting these private equity deals in Europe in H1 2024 were Kirkland & Ellis; Cuatrecasas, Goncalves Pereira; White & Case with 3, 2, 2 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q2 2024 – Thematic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.